Syringocystadenoma papilliferum associated with verrucous carcinoma of the skin in the same lesion: Report of four cases.
BRAF
V600E mutation
human papillomaviruses
syringocystadenoma papilliferum
verrucous carcinoma of the skin
Journal
Journal of cutaneous pathology
ISSN: 1600-0560
Titre abrégé: J Cutan Pathol
Pays: United States
ID NLM: 0425124
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
15
03
2019
revised:
07
08
2019
accepted:
16
08
2019
pubmed:
27
8
2019
medline:
5
6
2020
entrez:
27
8
2019
Statut:
ppublish
Résumé
The association of syringocystadenoma papilliferum (SCAP) with verrucous carcinoma (VC) of the skin in the same lesion is a rare, but well-documented event. Although human papillomaviruses (HPV) have been proposed to have an etiologic role in the development of the verrucous proliferations associated with SCAP, most of the immunohistochemical and molecular studies have failed to show the presence of their genomic material in these lesions. We report a series of four cases of SCAP associated with VC in anogenital lesions. In two of the cases, we demonstrated the presence of the BRAF
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Case Reports
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-16Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Requena L, Sangueza OP. Syringocystadenoma papilliferum. In: Requena L, Sangueza OP, eds. Cutaneous Adnexal Neoplasms. Switzerland: Springer International Publishing; 2017:55-64.
Shen AS, Peterhof E, Kind P, et al. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Hum Pathol. 2015;46(2):272-276.
Levinsohn JL, Sugarman JL, Bilguvar K, McNiff JM, Choate KA. The Yale Center for Mendelian genomics. Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum. J Invest Dermatol. 2015;135(10):2536-2538.
Watanabe Y, Shido K, Niihori T, et al. Somatic BRAF c.1799T>a p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. Am J Med Genet A. 2016;170A(1):189-194.
Konstantinova AM, Kyrpychova L, Nemcova J, et al. Syringocystadenoma papilliferum of the anogenital area and buttocks: a report of 16 cases, including human papillomavirus analysis and HRAS and BRAF V600 mutation studies. Am J Dermatopathol. 2019;41(4):281-285.
Contreras F, Rodriguez Peralto JL, Palacios J, Patrón M, Martin-Molinero R. Verrucous carcinoma of the skin associated with syringadenoma papilliferum: a case report. J Cutan Pathol. 1987;14(4):238-241.
Monticciolo NL, Schmidt JD, Morgan MB. Verrucous carcinoma arising within syringocystadenoma papilliferum. Ann Clin Lab Sci. 2002;32(4):434-437.
Park JH, Kim BY, Shin JJ, Kim IH. Syringocystadenoma papilliferum in coexistence with verrucous carcinoma on the face. Dermatol Surg. 2018;44(8):1144-1146.
Li A, Sanusi ID, Pena JR, Nopajaroonsri C, Kent M, Smoller BR. Syringocystadenoma papilliferum contiguous to a verrucous cyst. J Cutan Pathol. 2003;30(1):32-36.
Friedman BJ, Sahu J, Solomides CC, Connolly DM, Lee JB. Contiguous verrucous proliferations in syringocystadenoma papilliferum: a retrospective analysis with additional evaluation via mutation-specific BRAFV600E immunohistochemistry. J Cutan Pathol. 2018;45(3):212-216.
Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157(3):967-972.
Casadei Gardini A, Capelli L, Ulivi P, et al. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One. 2014;9(3):e92071.